MTPA's oral therapy Radicava (edaravone) has shown decreased functional decline and improved survival in long-term ALS trials ...

Neurizon Therapeutics has reported positive topline results from an open-label extension study of its lead candidate NUZ-001 ...

The ALS therapy ATH-1105 entered the brain and spinal cord at dose-proportional levels in healthy volunteers, and had a good ...

Summary: A new study has uncovered why some motor neurons resist degeneration in ALS while others succumb. Researchers found ...

Jodi O’Donnell-Ames founded Hope Loves Company to provide support, resources, and community to children affected by ALS.

A new brain-computer interface can decode a person's inner speech, which could help people with paralysis communicate.

By analyzing millions of messenger RNA molecules (mRNA) during the course of ALS, researchers at Stockholm University, in ...

The latest update is out from Neurosense Therapeutics Ltd. ( ($NRSN) ). As of August 20, 2025, NeuroSense Therapeutics Ltd. reported that ...

Stanford University scientists have developed a brain implant designed to "hear" and vocalize words a person with severe ...

David Crean, Chief Business Officer at MediciNova (Nasdaq: MNOV), a late-stage, global biopharmaceutical company that is ...

• Key Amyotrophic Lateral Sclerosis Pipeline Therapies: ION363, FB418, SRK-015, RNS60, QRL-201, SAR443820, MN-166, VM202, VRG-50635, Zilucoplan, and others.